KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Treasury Shares (2018 - 2025)

Historic Treasury Shares for Aquestive Therapeutics (AQST) over the last 8 years, with Q3 2025 value amounting to $2.9 million.

  • Aquestive Therapeutics' Treasury Shares rose 601.17% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year increase of 601.17%. This contributed to the annual value of $2.6 million for FY2024, which is 3398.36% up from last year.
  • As of Q3 2025, Aquestive Therapeutics' Treasury Shares stood at $2.9 million, which was up 601.17% from $3.3 million recorded in Q2 2025.
  • Aquestive Therapeutics' 5-year Treasury Shares high stood at $3.3 million for Q1 2025, and its period low was $8000.0 during Q2 2021.
  • Its 5-year average for Treasury Shares is $1.7 million, with a median of $1.9 million in 2023.
  • In the last 5 years, Aquestive Therapeutics' Treasury Shares crashed by 6818.18% in 2021 and then surged by 202500.0% in 2022.
  • Aquestive Therapeutics' Treasury Shares (Quarter) stood at $8000.0 in 2021, then soared by 1925.0% to $162000.0 in 2022, then soared by 1102.47% to $1.9 million in 2023, then surged by 33.98% to $2.6 million in 2024, then increased by 10.8% to $2.9 million in 2025.
  • Its Treasury Shares was $2.9 million in Q3 2025, compared to $3.3 million in Q2 2025 and $3.3 million in Q1 2025.